Ketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of neuroinflammation and soluble amyloid-beta peptide in depressive-like rats

Neuroscience Letters

Volumn 599, Issue , 2015, Pages 32-37

  Zhu, Xianlin ^a   Li, Ping ^a   Hao, Xuechao ^a   Wei, Ke ^a   Min, Su ^a   Luo, Jie ^a   Xie, Fei ^a   Jin, Juying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Amyloid ; Cytokines; Electroconvulsive shock; Ketamine; Memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CELL MARKER; IBA1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; KETAMINE; MESSENGER RNA; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; AMYLOID BETA-PROTEIN (1-42); ANTIINFLAMMATORY AGENT; CALCIUM BINDING PROTEIN; PEPTIDE FRAGMENT;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR CHANGE; BRAIN LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; ELECTROCONVULSIVE THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STRESS; SUCROSE PREFERENCE TEST; UPREGULATION; ANIMAL; DRUG EFFECTS; ELECTROSHOCK; GENETICS; HIPPOCAMPUS; INFLAMMATION; MAZE TEST; MEMORY DISORDERS; METABOLISM; PSYCHOLOGY; SOLUBILITY; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCIUM-BINDING PROTEINS; DEPRESSION; ELECTROSHOCK; HIPPOCAMPUS; INFLAMMATION; INTERLEUKIN-1BETA; KETAMINE; MALE; MAZE LEARNING; MEMORY DISORDERS; MICROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929624556     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.05.022     Document Type: Article

References (26)

1. Kessler R.C., Berlund P., Demler O., et al. The epidemiology of major depressive disorder: results for the national comorbidity survey replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Fraser L.M., O'Carroll R.E., Ebmeier K.P. The effect of electroconvulsive therapy on autobiographical memory: a systematic review. J. ECT 2008, 24(1):10-17.
3. McDaniel W.W., Sahota A.K., Vyas B.V., Laguerta N., Hategan L., Oswald J. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J. ECT 2006, 22(2):103-106.
4. Wang X., Chen Y., Zhou X., Liu F., Zhang T., Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J. ECT 2012, 28(2):128-132.
5. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
6. Xu P.X., Wang S.W., Yu X.L., Su Y.J., Wang T., Zhou W.W., Zhang H., Wang Y.J., Liu R.T. Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation. Behav. Brain Res. 2014, 264:173-180.
7. Nakamura Y. Regulating factors for microglial activation. Biol. Pharm. Bull. 2002, 25:945-953.
8. Barrientos R.M., Higgins E.A., Sprunger D.B., Watkins L.R., Rudy J.W., Maier S.F. Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus. Behav. Brain Res. 2002, 134:291-298.
9. Lahiri D.K., Chen D., Vivien D., Ge Y.W., Greig N.H., Rogers J.T. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimers disease. J. Alzheimers Dis. 2003, 5:81-90.
10. Lehtimaki K., Keranen T., Huuhka M., Palmio J., Hurme M., Leinonen E., Peltola J. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J. ECT 2008, 24:88-91.
11. Zhu X., Hao X., Luo J., Min S., Xie F., Zhang F. Propofol inhibits inflammatory cytokine-mediated glutamate uptake dysfunction to alleviate learning/memory impairment in depressed rats undergoing electroconvulsive shock. Brain Res. 2015, 1595:101-109.
12. Chang Y., Lee J.J., Hsieh C.Y., Hsiao G., Chou D.S., Sheu J.R. Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm. 2009, 2009:705379.
13. Banasr M., Valentine G.W., Li X.Y., Gourley S.L., Taylor J.R., Duman R.S. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol. Psychiatry 2007, 62(5):496-504.
14. Luo K.R., Hong C.J., Liou Y.J., Hou S.J., Huang Y.H., Tsai S.J. Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(8):1433-1439.
15. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13(10):1161-1169.
16. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67(8):793-802.
17. Bellinger F.P., Madamba S., Siggins G.R. Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res. 1993, 628(1-2):227-234.
18. Holmes C., Cunningham C., Zotova E., Culliford D., Perry V.H. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011, 77(3):212-218.
19. Butler M.P., O'Connor J.J., Moynagh P.N. Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124:319-326.
20. Wei W., Nguyen L.N., Kessels H.W., Hagiwara H., Sisodia S., Malinow R. Amyloid β from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 2010, 13:190-196.
21. Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus in vivo by β-amyloid precursor protein fragments. Neuroreport 1997, 8(15):3213-3217.
22. Lee M., McGeer E., McGeer P.L. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Neurobiol. Aging 2015, 36(1):42-52.
23. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005, 25(39):8843-8853.
24. Jantzen P.T., Connor K.E., Dicarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglia activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2002, 22(6):2246-2254.
25. Sheng J.G., Ito K., Skinner R.D., Mrak R.E., Rovnaghi C.R., Van Eldik L.J., Griffin W.S. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging 1996, 17(5):761-766.
26. Roses A.D. Causes or consequences of inflammation and pathological signs of Alzheimer disease. Neurobiol. Aging 2000, 21(3):423-425.